Researchers To Present New Data On Asfotase Alfa In Children With Hypophosphatasia (HPP) As Well As Burden Of Disease Data In Adults With HPP At ENDO 2015 Annual Meeting

Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) announced today that researchers will present new functional and quality-of-life data from clinical studies in children with hypophosphatasia (HPP) who were treated with asfotase alfa for at least three years at the Endocrine Society’s 97th Annual Meeting and Expo (ENDO). Researchers will also present data from two patient-reported surveys characterizing the burden of HPP in adults.

Help employers find you! Check out all the jobs and post your resume.